natgillin/translations-raw huggingface dataset:
The secondary definition of response required a 4-point or greater improvement on the ADAS-Cog, no worsening on the CIBIC-Plus, and no worsening on the PDS.
Za sekundarnu je definiciju odgovora bilo potrebno poboljšanje od 4 boda ili više na ADAS-Cog ljestvici, nikakvo pogoršanje na CIBIC- Plus ljestvici te nikakvo pogoršanje na PDS ljestvici.
The secondary efficacy endpoints in CP-CML were complete haematological response (CHR) and major molecular response (MMR).
Sekundarni ishodi za bolesnike u kroničnoj fazi KML bili su kompletni hematološki odgovor i veliki molekularni odgovor (MMR, engl. major molecular response).
The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all cause mortality.
Sekundarni ishod djelotvornosti definiran je kao spoj ponavljajućeg DVT-a, nesmrtonosne plućne embolije i smrtnosti od svih uzroka.
The secondary endpoint of complete resolution of heartburn, defined as no heartburn on the patient’s diary card for 7 consecutive days, was statistically significant at both week 1 (10.0% - 15.2% vs placebo 0.9% - 2.4%, p = 0.014, p<0.001) and week 2 (25.2% - 35.7% vs placebo 3.4% - 9.0%, p<0.001).
Sekundarna mjera ishoda potpunog povlačenja žgaravice definirana kao izostanak žgaravice na bolesnikovoj kartici tijekom posljednjih 7 uzastopnih dana bila je statistički značajna u oba tjedna (10% do 15,2% u odnosu na 0,9%-2,4% bolesnika koji su primali placebo, p=0,014, p<0,001) i tjedna 2 (25,2%-35,7% u odnosu na3,4%-9,0% bolesnika koji su primali placebo, p <0,001).
The secondary endpoint of Overall Survival (OS) was not mature .
Podaci za sekundarnu mjeru ishoda – ukupno preživljenje – nisu bili zreli.
The secondary endpoint of PFS showed no difference between Tarceva and placebo in maintenance treatment (HR=0.94, 95 % CI, 0.80 to 1.11; p=0.48).
Sekundarna mjera ishoda (PFS) nije pokazala razliku između lijeka Tarceva i placeba u terapiji održavanja (HR = 0,94; 95% CI: 0,80 – 1,11; p = 0,48).
The secondary endpoint of the study was overall survival.
Sekundarni ishod ispitivanja bilo je sveukupno preživljenje.
The secondary endpoints demonstrated that tafamidis meglumine treatment resulted in less deterioration of neurologic function and improved nutritional status (mBMI) compared with placebo, as shown in the following table.
Sekundarne mjere ishoda pokazale su da je terapija tafamidismegluminom rezultiralo manjim propadanjem neurološke funkcije i poboljšanim stanjem uhranjenosti (mBMI) u usporedbi s placebom, kako je prikazano u sljedećoj tablici.
The secondary endpoints in the table above reached statistical significance in the whole population.) The secondary endpoints of combined all cause death or life-threatening experience, all cause death, or all cause hospitalisation did not reach statistical significance in the whole population.
Sekundarni ishodi u gornjoj tablici postigli su statističku značajnost u cijeloj populaciji.) Sekundarni ishodi kombinirane smrti svih uzroka ili životno ugrožavajućeg događaja, smrt svih uzroka, ili hospitalizacija svih uzroka nisu postigli statističku značajnost u cijeloj populaciji.
The secondary endpoints included overall survival (OS), overall response rate (ORR) [PR+CR], time to response, duration of response, and time to treatment failure (time from randomisation until the first episode of clinically relevant disease progression where there is no response achieved after the progression event, or until death).
Sekundarni ishodi uključivali su ukupno preživljenje (OS, od eng. overall survival), učestalost sveukupnog odgovora (ORR, od eng. overall response rate) [PR+CR], vrijeme do odgovora, trajanje odgovora i vrijeme do neuspjeha liječenja (vrijeme od randomizacije do prvog događaja klinički relevantne progresije bolesti gdje nije postignut odgovor nakon događaja progresije ili do smrti).
The secondary endpoints were progression-free survival in the ITT population and overall survival (OS), overall response rate (ORR), and duration of response in the primary efficacy population and ITT population.
Mjere sekundarnog ishoda bile su preživljenje bez progresije bolesti u ITT populaciji te ukupno preživljenje (engl. overall survival, OS), stopa ukupnog odgovora (engl. overall response rate, ORR) i trajanje odgovora u primarnoj populaciji za ispitivanje djelotvornosti i ITT populaciji.
The secondary endpoints were the change from baseline in the 3 Minute Stair Climb Test (MSCT) and urine KS levels at Week 24.
Sekundarne mjere ishoda bile su promjene od početne vrijednosti u 3-minutnom testu penjanja stepenicama (3 Minute Stair Climb Test) i razinama KS-a u mokraći u 24. tjednu.
The secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with rivaroxaban 20 mg once daily compared to placebo.
Sekundarni ishod sigurnosti (veća ili klinički značajna manja krvarenja) pokazao je više stope kod bolesnika liječenih rivaroksabanom od 20 mg jedanput na dan u odnosu na placebo.
The secretory pathway appears not to include known acidic or basic transport systems involved in the excretion of other active substances.(see section 4.5).
Čini se da put izlučivanja putem bubrega ne obuhvaća poznate kisele ni bazne transportne sustave uključene u izlučivanje drugih djelatnih tvari (vidjeti dio 4.5).
The section 4.4 of the summary of product characteristics and the relevant sections of the package leaflet were updated.
Ažurirani su dio 4.4 sažetka opisa svojstava lijeka i odgovarajući dijelovi upute o lijeku.
The sedative effect may be enhanced when the product is used in combination with alcohol which may affect the ability to drive or use machines the next day (see section 4.7).
Kada se lijek uzima u kombinaciji s alkoholom, sedativni učinak se može pojačati što može utjecati na sposobnost upravljanja vozilima ili rada sa strojevima sljedeći dan (vidjeti dio 4.7).
The SELECT study was a multicentre, randomised, double-blind, placebo-controlled trial that was conducted in 392 patients with radioiodine-refractory differentiated thyroid cancer with independent, centrally reviewed, radiographic evidence of disease progression within 12 months (+1 month window) prior to enrollment.
Ispitivanje SELECT bilo je multicentrično, randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno u 392 bolesnika s diferenciranim rakom štitnjače refraktornim na radioaktivni jod i s neovisno, centralno pregledanim radiografskim dokazom progresije bolesti unutar 12 mjeseci (u rasponu od +1 mjesec) prije uključenja.
The selected viruses were unable to grow in the presence of darunavir concentrations above 400 nM.
Odabrani virusi nisu mogli rasti u prisutnosti darunavira u koncentracijama iznad 400 nM.
The selection of 0.2 mg/kg dose (infused over 40 minutes) for the registration clinical studies was intended to temporarily saturate the ability of the mannose-6- phosphate receptors to internalize the agalsidase alfa in the liver and allow distribution of enzyme to other relevant organ tissues.
Odabir doze od 0,2 mg/kg (primjenjivane infuzijom tijekom 40 minuta) za klinička ispitivanja za registraciju lijeka bio je namijenjen privremenom zasićivanju sposobnosti receptora za manozu-6-fosfat za unos agalzidaze alfa u jetru i omogućivanju distribucije enzima u druga relevantna organska tkiva.
The selection of formulation is based on individual characteristics of the patient.
Odabir farmaceutskog oblika ovisi o osobinama pojedinog bolesnika.
The selection of formulation is based on individual characteristics of the patient..
Odabir farmaceutskog oblika ovisi o osobinama pojedinog bolesnika.
The selection of resistance to lopinavir in patients having failed prior protease inhibitor therapy was characterised by analysing the longitudinal isolates from 19 protease inhibitor-experienced subjects in 2 Phase II and one Phase III studies who either experienced incomplete virologic suppression or viral rebound subsequent to initial response to Kaletra and who demonstrated incremental in vitro resistance between baseline and rebound (defined as emergence of new mutations or 2-fold change in phenotypic susceptibility to lopinavir).
Rezistencija na lopinavir u bolesnika u kojih prethodna terapija inhibitorom proteaze nije uspjela određena je analizom longitudinalnih izolata 19 bolesnika koji su prethodno bili na terapiji inhibitorom proteaze iz dva istraživanja faze II i jednog istraživanja faze III, a u kojih je zamijećena ili nepotpuna virusna supresija ili ponovni porast broja virusa (rebound) nakon početnog odgovora na lijek Kaletra te u kojih je primijećen in vitro porast rezistencije u fazi ponovnog porasta broja virusa (definiran kao pojava nove mutacije ili dvostruka promjena fenotipske osjetljivosti na lopinavir) u odnosu na početak.
The selection of resistance to lopinavir in patients having failed prior protease inhibitor therapy was characterised by analysing the longitudinal isolates from 19 protease inhibitor-experienced subjects in 2 Phase II and one Phase III studies who either experienced incomplete virologic suppression or viral rebound subsequent to initial response to lopinavir/ritonavir and who demonstrated incremental in vitro resistance between baseline and rebound (defined as emergence of new mutations or 2-fold change in phenotypic susceptibility to lopinavir).
Rezistencija na lopinavir u bolesnika u kojih prethodna terapija inhibitorom proteaze nije uspjela određena je analizom longitudinalnih izolata 19 bolesnika koji su prethodno bili na terapiji inhibitorom proteaze iz dva istraživanja faze II i jednog istraživanja faze III, a u kojih je zamjećena ili nepotpuna virusna supresija ili ponovni porast broja virusa (rebound) nakon početnog odgovora na lopinavir/ritonavir te u kojih je primjećen in vitro porast rezistencije u fazi ponovnog porasta broja virusa (definiran kao pojava nove mutacije ili dvostruka promjena fenotipske osjetljivosti na lopinavir) u odnosu na početak.
The selection of the pre-set programme is made by the physician.
Odluku o odabiru unaprijed određenog programa donosi liječnik.
The selective antagonism of the angiotensin-II (AT1 ) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration.
Selektivni antagonizam receptora angiotenzina II (AT1) za ishod ima povećanje razine renina u plazmi i razine angiotenzina II te snižavanje koncentracije aldosterona u plazmi.
The selective toxicity of afoxolaner between insect/acarines and mammals may be inferred by the differential sensitivity of the insect/acarines’ GABA receptors versus mammalian receptors.
Selektivna toksičnost afoksolanera za kukce/akaride i sisavce se može zaključiti po različitoj osjetljivosti GABA receptora insekata/akarida u odnosu na receptore sisavaca.
The selective toxicity of afoxolaner between insects, acarines and mammals may be inferred by the differential sensitivity of the insects and acarines’ GABA receptors versus mammalian GABA receptors.
Selektivna toksičnost afoksolanera za insekte /akaride i sisavce se može zaključiti po različitoj osjetljivosti GABA receptora insekata/akarida u odnosu na receptore sisavaca.
The selectivity of ambrisentan for the ETA over the ETB receptor is expected to retain ETB receptor mediated production of the vasodilators nitric oxide and prostacyclin.
Zbog selektivnosti ambrisentana za ETA receptore u odnosu na ETB receptore, očekuje se održano stvaranje vazodilatatora – dušikovog oksida i prostaciklina, posredovano ETB receptorima.
The selectivity of PDT using verteporfin is based, in addition to the localised light exposure, on selective and rapid uptake and retention of verteporfin by rapidly proliferating cells including the endothelium of choroidal neovasculature.
Selektivnost fotodinamske terapije (PDT – photodynamic therapy) verteporfinom zasniva se, osim na lokaliziranoj izloženosti svjetlosti, i na selektivnom i brzom ulasku i zadržavanju verteporfina u stanicama koje brzo proliferiraju, uključujući endotel neovaskulature žilnice.
The sensitivity of the vaccine strain to antibiotics is listed above.
Osjetljivost cjepnog soja na antibiotike je naznačena (u odjeljku 4.4).
The sensitivity ranged from 60.6% to 63.4% and specificity from 88.6% to 91.4% when the possible DLB patients were included as DLB patients.
Osjetljivost je bila u rasponu od 60,6% do 63,4% a specifičnost od 88,6% do 91,4% kad su mogući DLT pacijenti bili uključeni kao DLT pacijenti.
The separate pharmaceutical forms of efavirenz, emtricitabine and tenofovir disoproxil fumarate were used to determine the pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil fumarate, administered separately in HIV infected patients.
Zasebni farmaceutski oblici efavirenza, emtricitabina i tenofovirdizoproksilfumarata korišteni su da bi se utvrdila farmakokinetika efavirenza, emtricitabina i tenofovirdizoproksilfumarata koji su zasebno davani pacijentimainficiranima virusom HIV-a.
The separation between the treatment arms was achieved by improvement in lung function in the pemetrexed /cisplatin arm and deterioration of lung function over time in the control arm.
Razlikovanje između liječenih skupina postiglo se poboljšanjem funkcije pluća u skupini liječenoj kombinacijom pemetreksed/cisplatin i pogoršanjem funkcije pluća tijekom vremenau kontrolnoj skupini.
The separation between the treatment arms was achieved by improvement in lung function in the pemetrexed/cisplatin arm and deterioration of lung function over time in the control arm.
Skupine su se razlikovale i po tome što se u bolesnika liječenih kombinacijom pemetrekseda/cisplatin funkcija pluća poboljšala, dok se u kontrolnoj skupini s vremenom pogoršavala.
The sequential administration of combined dTpa-IPV followed by Cervarix one month later tended to elicit lower anti-HPV-16 and anti-HPV-18 GMTs as compared to Cervarix alone.
Sekvencijsko cijepljenje cjepivom Cervarix mjesec dana nakon cijepljenja kombiniranim cjepivom dTpa-IPV pokazuje trend pojave nižih geometrijskih srednjih titara anti- HPV-16 i anti-HPV-18 antitijela, nego nakon cijepljenja samim cjepivom Cervarix.
The sequential administration of Nimenrix one month after a DTaP-HBV-IPV/Hib vaccine resulted in lower GMTs for antibody against groups A, C and W-135.
Davanje cjepiva Nimenrix mjesec dana nakon cjepiva DTaP-HBV-IPV/Hib rezultiralo je nižim GMT za antitijela na grupe A, C i W-135.
The serious adverse reactions observed more frequently (≥5%) with lenalidomide in combination with low dose dexamethasone (Rd and Rd18) than with melphalan, prednisone and thalidomide (MPT) were:
Ozbiljne nuspojave opažene češće (≥ 5%) za lenalidomid u kombinaciji s niskom dozom deksametazona (Rd i Rd18) nego za melfalan, prednizon i talidomid (MPT) bile su:
The serious adverse reactions observed more frequently (≥5%) with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance (MPR+R) or melphalan, prednisone and lenalidomide followed by placebo (MPR+p) than melphalan, prednisone and placebo followed by placebo (MPp+p) were:
Ozbiljne nuspojave opažene su češće (≥ 5%) uz melfalan, prednizon i lenalidomid nakon čega je slijedila terapija održavanja lenalidomidom (MPR+R) ili uz melfalan, prednizon i lenalidomid nakon čega je slijedio placebo (MPR+p), nego uz melfalan, prednizon i placebo nakon čega je slijedio placebo (MPp+p), a bile su:
The serious adverse reactions observed more frequently in Study MCL-002 (with a difference of at least 2 percentage points) in the lenalidomide arm compared with the control arm were:
Ozbiljne nuspojave koje su u ispitivanju MCL-002 češće opažene (s razlikom od najmanje 2 postotna boda) u skupini liječenoj lenalidomidom u usporedbi s kontrolnom skupinom bile su:
The seropositivity rate for anti-HAV antibodies after Twinrix Adult was 97% at both 7 and 48 months versus 99% and 93% after the GlaxoSmithKline Biologicals monovalent hepatitis A vaccine and 99% and 97% after another licensed monovalent hepatitis A vaccine.
Stopa seropozitivnost za anti-HAV protutijela nakon primjene cjepiva Twinrix Adult je iznosila 97% i nakon 7 i nakon 48 mjeseci, naspram na 99% odnosno 93% nakon primjene GlaxoSmithKline Biologicals monovalentnog cjepiva protiv hepatitisa A, te 99% odnosno 97% nakon primjene jednog drugog monovalentnog cjepiva protiv hepatitisa A.
The seroprotection at month 6, 12 and 24 were as follows:
Stope seroprotekcije u 6., 12. i 24. mjesecu bile su sljedeće:
The seroprotection rate against A/Indonesia 21 days after booster vaccination was 92% and 69.2% at day 180.
Stopa seroprotekcije protiv A/Indonesia 21 dan nakon docjepljivanja bila je 92%, a 180.-ti dan 69,2%.
The seroprotection rate and seroconversion rate measured by HI assay and the seroconversion factor expressed as geometric mean ratios of HI for anti-HA antibody to H1N1 after administration of one and two 7.5 µg doses of Focetria was evaluated in 70 children and adolescents (9-17 years), 60 children (3-8 years), 58 children (12-35 months) and 49 infants (6-11 months).
Stupanj serozaštite, stupanj serokonverzije izmjereni HI testom i čimbenik serokonverzije izražen kao koeficijent geometrijske sredine HI za anti-HA protutijelo na H1N1 nakon primjene jedne ili dviju doza od 7,5 µg Focetrie je procijenjen u 70 djece i adolescenata (9-17 godina), 60 djece (3-8 godina), 58 djece (12-35 mjeseci) te 49 dojenčadi (6-11 mjeseci).
The seroprotection rate and seroconversion rate measured by HI assay and the seroconversion factor expressed as geometric mean ratios of HI for anti-HA antibody to H1N1 after administration of one and two7.5 µg doses of Focetria was evaluated in 70 children and adolescents (9-17 years), 60 children (3-8 years), 58 children (12-35 months) and 49 infants (6-11 months).
Stupanj serozaštite, stupanj serokonverzije izmjereni HI testom i čimbenik serokonverzije izražen kao koeficijent geometrijske sredine HI za anti-HA protutijelo na H1N1 nakon primjene jedne ili dviju doza od 7,5 µg Focetrie je procijenjen u 70 djece i adolescenata (9-17 godina), 60 djece (3-8 godina), 58 djece (12-35 mjeseci) te 49 dojenčadi (6-11 mjeseci).
The seroprotection rate at month 6, 12 and 24 were as follows:
Stope seroprotekcije u 6., 12. i 24. mjesecu bile su sljedeće:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H1N1v in children aged 12-35 months by HI assay after administration of 7.5 µg of Focetria were as follows:
Stopa serozaštite*, stopa serokonverzije* i faktor serokonverzije** za anti-HA protutijelo na H1N1v u djece u dobi 12-35 mjeseci pomoću HI analize nakon primjene 7,5 µg Focetrie bili su kako slijedi:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H1N1v in children aged 12-35 months by HI assay after administration of 7.5 µg of Focetria were as follows:
u djece u dobi od 12-35 mjeseci pomoću HI analize nakon primjene 7,5 µg Focetrie bili su kako slijedi:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H1N1v in children aged 3-8 years by HI assay after administration of 7.5 µg of Focetria were as follows:
Stopa serozaštite*, stopa serokonverzije* i faktor serokonverzije** za anti-HA protutijelo na H1N1v u djece u dobi 3-8 godina pomoću HI analize nakon primjene 7,5 µg Focetrie bili su kako slijedi:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H1N1v in children and adolescents aged 9-17 years by HI assay administration of 7.5 µg of Focetria were as follows:
Stopa serozaštite*, stopa serokonverzije* i faktor serokonverzije** za anti-HA protutijelo na H1N1v u djece i adolescenata u dobi od 9-17 godina pomoću HI analize nakon primjene 7,5 µg Focetrie bili su kako slijedi:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 and to A/H5N1/turkey/Turkey/1/05 (Study V87P11) in subjects aged over 60 (limited number of subjects were above 70 years of age) measured by SRH assay assessed in three clinical studies were as follows:
Stopa seroprotekcije*, stopa serokonverzije* i čimbenik serokonverzije** za anti-HA protutijela na virus H5N1 A/Vietnam/1194/2004 i na virus A/H5N1/turkey/Turkey/1/05 (Studija V87P11) u ispitanika starijih od 60 godina (ograničen broj ispitanika bio je stariji od 70 godina) izmjereni SRH analizom i procijenjeni u tri klinička ispitivanja bili su sljedeći:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 and to A/H5N1/turkey/Turkey/1/05 in the adults measured by SRH assay was as follows:
Stopa seroprotekcije*, stopa serokonverzije* i čimbenik serokonverzije** za anti-HA protutijela na virus H5N1 A/Vietnam/1194/2004 i na virus A/H5N1/turkey/Turkey/1/05 u odraslih osoba izmjereni SRH analizom bili su sljedeći:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in subjects aged over 60 (limited number of subjects were above 70 years of age) measured by SRH assay assessed in two clinical studies were as follows:
Stopa serozaštite*, stopa serokonverzije* i čimbenik serokonverzije** za anti-HA protutijela na H5N1 virus A/Vietnam/1194/2004 u ispitanika starijih od 60 godina (ograničen broj ispitanika bio je stariji od 70 godina) izmjereni SRH analizom i procijenjeni u dva klinička ispitivanja bili su sljedeći:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in subjects aged over 60 (limited number of subjects were above 70 years of age) measured by SRH assay assessed in two clinical studies were as follows:
Stopa serozaštite*, stopa serokonverzije* i čimbenik serokonverzije** za anti-Ha protutijela na virus H5N1 A/Vietnam/1194/2004 u ispitanika starijih od 60 godina (ograničen broj ispitanika bio je stariji od 70 godina) izmjereni SRH analizom i procijenjeni u dva klinička ispitivanja bili su sljedeći:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in the adults measured by SRH assay was as follows:
Stopa serozaštite*, stopa serokonverzije* i čimbenik serokonverzije** za anti-HA protutijela na virus H5N1 A/Vietnam/1194/2004 u odraslih osoba izmjereni SRH analizom bili su sljedeći:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 measured by SRH assays were as follows:
Stopa seroprotekcije*, stopa serokonverzije* i čimbenik serokonverzije** za anti-HA protutijela na virus H5N1 A/Vietnam/1194/2004 izmjereni SRH analizama bili su sljedeći:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 measured by SRH assays were as follows:
Stopa serozaštite*, stopa serokonverzije* i čimbenik serokonverzije** za anti-HA protutijela na virus H5N1 A/Vietnam/1194/2004 izmjereni SRH analizom bili su sljedeći:
The seroprotection rate, booster seroconversion rate and booster factor against A/Indonesia/5/2005 21 days after booster vaccination was 100%, 99.7% and 123.8%, respectively.
Stopa seroprotekcije, stopa serokonverzije docjepljivanja i čimbenik docjepljivanja protiv A/Indonesia/5/2005, 21 dan nakon docjepljivanja bili su redom 100%, 99,7% i 123,8%.
The seroprotection rates 6, 12 and 24 months after vaccination were as follows:
Zabilježene su sljedeće stope seroprotekcije u razdobljima 6, 12 i 24 mjeseca nakon cijepljenja:
The seroprotection rates 6, 12 and 24 months after vaccination were as follows:
Zabilježeni su sljedeći stupnjevi seroprotekcije u razdobljima 6, 12 i 24 mjeseca nakon cijepljenja:
The seroprotection rates 6, 12, 24 and 36 months after the first dose were as follows:
Stope seroprotekcije u razdobljima 6, 12, 24 i 36 mjeseca nakon prve doze bile su sljedeće:
The seroprotection rates 6, 12, 24 and 36 months after the first dose were as follows:
Zabilježeni su sljedeće stope seroprotekcije u razdobljima 6, 12, 24 i 36 mjeseci nakon prve doze:
The seroprotection rates were 16.3% and 4.7% at months 12 and 24, respectively.
Stopa seroprotekcije u 12. mjesecu bila je 16,3%, a u 24. mjesecu 4,7%.